Selective neuronal vulnerability following mild focal brain ischemia in the mouse

Brain Pathol. 2003 Oct;13(4):452-64. doi: 10.1111/j.1750-3639.2003.tb00476.x.

Abstract

The evolution of cellular damage over time and the selective vulnerability of different neuronal subtypes was characterized in the striatum following 30-minute middle cerebral artery occlusion and reperfusion in the mouse. Using autoradiography we found an increase in the density of [3H]PK11195 binding sites--likely reflecting microglial activation--in the lesion border at 3 days and in the whole striatum from 10 days to 6 weeks. This was accompanied by a distinct loss of [3H]flumazenil and [3H]CGP39653 binding sites from 10 days up to 6 weeks reflecting neuronal loss. Brain ischemia resulted in a substantial loss of medium spiny projection neurons as seen at three days by Nissl staining, TUNEL and immunocytochemistry using antibodies against microtubule-associated protein (MAP2), NeuN, mu-opioid receptors, substance P, L-enkephalin, neurokinin B, choline acetyltransferase, parvalbumin, calretinin and somatostatin. Both patch and matrix compartments were involved in ischemic damage. In contrast, the numbers of cholinergic, GABAergic, and somatostatin-containing interneurons in the ischemic striatum were not different from those in the contralateral hemisphere at 3 and 14 days. A low density of glutamate receptors, the ability to sequester calcium by calcium-binding proteins and other hitherto unidentified factors may explain this relative resistance of interneurons to acute ischemia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 2-Amino-5-phosphonovalerate / analogs & derivatives*
  • 2-Amino-5-phosphonovalerate / pharmacokinetics
  • Animals
  • Antidotes / pharmacokinetics
  • Antineoplastic Agents / pharmacokinetics
  • Autoradiography / methods
  • Binding Sites
  • Brain Ischemia / etiology
  • Brain Ischemia / physiopathology*
  • Calbindin 2
  • Cell Count / methods
  • Cell Survival*
  • Choline O-Acetyltransferase / metabolism
  • Corpus Striatum / drug effects
  • Corpus Striatum / pathology*
  • Disease Models, Animal
  • Excitatory Amino Acid Antagonists / pharmacokinetics
  • Flumazenil / pharmacokinetics
  • Functional Laterality
  • Immunohistochemistry / methods
  • In Situ Nick-End Labeling / methods
  • Infarction, Middle Cerebral Artery / complications
  • Isoquinolines / pharmacokinetics
  • Mice
  • Neurons / drug effects
  • Neurons / pathology*
  • Parvalbumins
  • Phosphopyruvate Hydratase / metabolism
  • S100 Calcium Binding Protein G / metabolism
  • Somatostatin / metabolism
  • Staining and Labeling
  • Time Factors
  • Tritium / pharmacokinetics

Substances

  • Antidotes
  • Antineoplastic Agents
  • Calb2 protein, mouse
  • Calbindin 2
  • Excitatory Amino Acid Antagonists
  • Isoquinolines
  • Parvalbumins
  • S100 Calcium Binding Protein G
  • Tritium
  • CGP 39653
  • Flumazenil
  • Somatostatin
  • 2-Amino-5-phosphonovalerate
  • Choline O-Acetyltransferase
  • Phosphopyruvate Hydratase
  • PK 11195